$ Value
$477K
Shares
1,960
Price
$243
Filed
Feb 18
Insider
Name
Duato Joaquin
Title
CEO and Chairman of the Board
CIK
0001673401
Roles
Transaction Details
Transaction Date
2026-02-15
Code
F
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
324,447
Footnotes
Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of RSUs. | Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of PSUs. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. | Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026). | Each RSU represents a contingent right to receive one share of Company Common Stock. | Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
Filing Info
Duato Joaquin's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $390K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $477K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-13 | JNJ | M | $0 |
| 2026-02-13 | JNJ | F | $242K |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $21.8M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | $1.0M | 2026-02-27 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.9M | 2026-02-20 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |